---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Efficacy and safety"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Efficacy and safety. Topics: Summary: design of the source studies and the pooled analysis; Summary: efficacy versus the Enroll-HD external control at 36 and 48 months; Summary: interim comparisons with other natural history controls, 2023 and 2024; Summary: safety; 1 further topic. 5 evidence topics quoted from 25 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary/efficacy-and-safety"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Ifezuntirgene inilparvovec Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary: design of the source studies and the pooled analysis

- Ifezuntirgene inilparvovec (AMT-130) is given once, by MRI-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum (caudate and putamen). The registry records list a low dose of 6x10^12 gc/subject and a high dose of 6x10^13 gc/subject.
- CT-AMT-130-01 (United States): in Cohorts 1 and 2, 26 participants with early manifest Huntington's disease were randomized to the low dose (6), the high dose (10), or an imitation (sham) surgical procedure (10), with a blinded 12-month period followed by unblinded long-term follow-up. In Cohort 3, 12 participants were blinded and randomized to the high dose (n=6) or the low dose (n=6) with an immunosuppression regimen. Cohort 4 enrolled six participants with lower striatal volumes, all receiving the high dose. The registered primary outcome is adverse events, assessed at 12 months.
- CT-AMT-130-02 (Europe): the Form 10-K reports 13 participants enrolled and treated in this open-label study (six low dose, seven high dose); the ClinicalTrials.gov record lists an actual enrollment of 14.
- Pooled analysis: two additional protocols pool data across the U.S. and EU studies and prespecify a comparison with a propensity score-matched external control from the Enroll-HD natural history data set. Matching covariates were baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR. Eligibility required age 25-65 years, TFC 9-13, and striatal volumes above specified minima. The primary endpoint is change from baseline in cUHDRS at 36 months; secondary endpoints are TFC, SDMT, SWRT, and TMS; CSF NfL change at 36 months is supportive.
- Primary comparison: the June 2025 release described a propensity score-weighted external control for the primary analysis, with a propensity score-matched control as a sensitivity analysis; the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis.
- Participants: the three-year analysis (data cutoff June 30, 2025) covered 29 treated participants (17 high dose, 12 low dose), of whom 12 per dose group had 36 months of follow-up, against Enroll-HD controls of n=940 (high dose) and n=626 (low dose). The four-year and updated 36-month analyses (data cutoff June 30, 2026) used an updated Enroll-HD dataset with a September 2025 cutoff (n=1,337 for high dose, Enroll-HD B) for the primary comparison and the earlier dataset (Enroll-HD A, N=619) for a post hoc comparison.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493); [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017); [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-1.1.2-2"></a>

### Summary: efficacy versus the Enroll-HD external control at 36 and 48 months

- Three-year analysis, high dose (12 participants at 36 months; data cutoff June 30, 2025): mean change in cUHDRS from baseline was -0.38 compared with -1.52 for the propensity score-matched external control, a 75% slowing of disease progression (p=0.003), which met the primary endpoint. Mean change in TFC was -0.36 compared with -0.88, a 60% slowing (p=0.033), which met a key secondary endpoint. SDMT showed an 88% slowing (p=0.057; -0.44 compared with -3.73). The Form 10-K reports a 113% slowing on SWRT (nominal p=0.002; 0.88 compared with -6.98) and a 59% slowing on TMS (nominal p=0.174; 2.01 compared with 4.88). Mean CSF NfL changed by -8.2% from baseline (N=11 in the presentation).
- Three-year analysis, low dose (N=12): LSM change in cUHDRS was -1.65 compared with -1.72 for the external control (difference 0.07 [95% CI -0.75, 0.88]; p=0.871). The TFC difference was 0.71 [0.12, 1.31] (p=0.019), and LSM change in SDMT was -6.44 compared with -3.35 (difference -3.09; p=0.046). The presentation states that these p-values are nominal and that hierarchical testing was discontinued for p-value >0.05. Mean CSF NfL changed by -4.7%. The company attributes the contrast between doses to a “dose-dependent response”.
- Updated 36-month analysis, high dose (15 participants; data cutoff June 30, 2026; Enroll-HD B): cUHDRS changed by -0.28 compared with -1.39, an 80% slowing (nominal p=0.005); TFC changed by -0.27 compared with -0.82, a 67% slowing (nominal p=0.011). The presentation reports slowing of 124% on SDMT (p=0.040), 123% on SWRT (p=0.047), and 59% on TMS (p=0.114), with nominal p-values. Mean CSF NfL was 6% below baseline (n=14).
- 48-month primary analysis, high dose (12 participants; Enroll-HD B): cUHDRS changed by -0.90 compared with -1.61, a 44% slowing that did not reach statistical significance (p=0.144). TFC changed by -0.37 compared with -0.94, a 61% slowing (nominal p=0.008). The presentation reports slowing of 113% on SWRT (p=0.006), 20% on SDMT (p=0.731), and 5.6% on TMS (p=0.908). Mean CSF NfL was 4% above baseline for the high dose (n=11) and 8% below baseline for the low dose.
- 48-month post hoc analysis against Enroll-HD A (N=619): the release reports 53.5% slowing on cUHDRS (nominal p=0.041) and 68.3% on TFC (nominal p=0.001); the presentation reports 54% (p=0.041) and 68% (p<0.001).
- Dose comparison at 48 months: the four-year release reports mean change in cUHDRS of -0.91 for the high dose and -1.94 for the low dose (a difference of 1.03) and in TFC of -0.30 and -0.70 (a difference of 0.40); the third quarter 2026 release reports 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC for the high dose.
- Missing data in the updated Enroll-HD matched controls reached 53% at 48 months, and the company states that this likely understated progression in the control group.

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-1.1.2-3"></a>

### Summary: interim comparisons with other natural history controls, 2023 and 2024

- December 2023 (data cutoff September 30, 2023): treated participants were compared with a non-concurrent criteria-matched cohort of 31 participants from the TRACK-HD natural history study, excluding efficacy data from control participants who crossed over to treatment. The favorable difference in cUHDRS was 0.39 points at 30 months for the low dose and 1.24 points at 18 months for the high dose; for TFC it was 0.95 points at 30 months and 0.49 points at 18 months.
- July 2024 (data cutoff March 31, 2024; 24-month data from 21 participants, 12 low dose and 9 high dose): compared with a propensity-weighted external control (n=154) from the TRACK-HD, TRACK-ON, and PREDICT-HD studies, mean change in cUHDRS was -0.2 for the high dose and -1.0 for the control, an 80% slowing (p=0.007), and -0.7 for the low dose, a 30% slowing (p=0.21). Mean CSF NfL was reduced by 11% from baseline (p=0.02). The Form 10-K describes this comparison as a post-hoc analysis.

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene); [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-1.1.2-4"></a>

### Summary: safety

- The most common adverse events in the treatment groups were related to the administration procedure, and all resolved.
- June 30, 2025 data cutoff (Cohorts 1 to 3, n=45 treated; sham surgery n=10): any treatment-emergent adverse event occurred in 44 (97.8%) treated participants, any serious adverse event in 15 (33.3%), a peri-operative serious adverse event in 8 (17.8%), a drug-related adverse event in 9 (20.0%), and a drug-related serious adverse event in 4 (8.8%); 1 (10.0%) sham participant had a serious adverse event. The most frequent events among treated participants were headache (18, 40.0%), procedural headache (16, 35.6%), procedural pain (11, 24.4%), and post lumbar puncture syndrome (10, 22.2%).
- June 30, 2026 data cutoff (Cohorts 1 to 4, n=51 treated): any treatment-emergent adverse event 50 (98%), any serious adverse event 20 (39.2%), peri-operative serious adverse event 9 (17.6%), drug-related adverse event 11 (21.5%), drug-related serious adverse event 5 (9.80%), and headache 21 (41.2%).
- Central nervous system inflammation: in July 2022 the company reported suspected unexpected severe adverse reactions in three of the 14 participants treated with the high dose, and in October 2022 the Data Safety Monitoring Board recommended resuming the high dose with additional risk mitigation procedures during the first two weeks after administration. The four-year release states that five high dose participants (17%) experienced a treatment-related serious adverse event related to central nervous system inflammation, all of which fully resolved. The four-year presentation reports one such event in a Cohort 4 participant, which resolved after a short course of corticosteroids.
- In Cohort 3, three serious adverse events related to immunosuppression (mania, infection, and fever) resolved with supportive care, and no treatment-related serious adverse events were reported.
- One low-dose participant died by suicide approximately five years after treatment; the study investigator assessed the event as unrelated to treatment.

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and); [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-1.1.2-5"></a>

### Summary: regulatory context for the external control comparison

- In 2024 the company reported that, at a Type B meeting held in late November, the FDA agreed that phase I/II data compared with a natural history external control may serve as the primary basis for a BLA under the Accelerated Approval pathway, with cUHDRS as an intermediate clinical endpoint and CSF NfL reductions as supportive evidence.
- After the October 29, 2025 pre-BLA meeting, the company stated its belief that the FDA no longer agreed that the external control comparison may be adequate as primary evidence, and the final minutes stated that the phase I/II data were “currently unlikely to provide the primary evidence” to support a BLA submission. After a Type A meeting on January 30, 2026, the FDA stated that it cannot agree that these data are sufficient and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.
- After a Type B meeting, the company reported in 2026 that the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval, and minutes received in July 2026 confirmed that a submission based on the existing clinical data is reasonable.
- The Form 10-Q states that the company announced the BLA submission in September 2026 and, in a separate passage, that the BLA was submitted in August 2026 and accepted in October 2026; it also states that acceptance was announced on November 2, 2026. The application has Priority Review with a PDUFA target action date of May 1, 2027, and the FDA is tentatively planning an Advisory Committee meeting. The BLA is supported by 36-month data from 12 high-dose participants compared with a propensity score-matched external control, and the 48-month results were not part of the BLA or the UK MAA, which the MHRA validated in the third quarter of 2026.
- The confirmatory trial is designed as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint; screening is planned to begin in the United States by the end of 2026.

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated); [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0); [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons); [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
